Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01968980 · ClinicalTrials.gov registry record · Phase 3
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A Phase 3 study of Heterozygous Familial Hypercholesterolemia, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 370
- Enrollment target
- 20
- Study locations
NCT01968980 is a Phase 3 study of Heterozygous Familial Hypercholesterolemia that has completed, run by Pfizer. The registered enrollment target is 370 participants, above the 171-participant average among 4 other Heterozygous Familial Hypercholesterolemia trials with a reported enrollment target (116% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT01968980, a Phase 3 study of Heterozygous Familial Hypercholesterolemia, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 370 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized study in subjects with heterozygous familial hypercholesterolemia receiving highly effective statins to assess the safety, efficacy and tolerability of Bococizumab (PF-04950615; RN316) to lower LDL-C.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Bococizumab (PF-04950615;RN316)
Study Locations (20)
Florida
- Best Quality Research, Inc. - Hialeah
- Medical Research Center - Miami
- Premier Research Associate, Inc - Miami
- Columbus Clinical Services, LLC - Miami
- NewPhase Clinical Trials, Corp. - Miami Beach
Texas
- Galenos Research - Dallas
- UT Southwestern Medical Center - Dallas
- Pioneer Research Solutions, Inc. - Houston
- Pioneer Research Solutions, Inc. - Sugar Land
Oklahoma
- Oklahoma Heart Hospital Physicians - Oklahoma City
- Oklahoma Heart Hospital Research Foundation - Oklahoma City
- Oklahoma Heart Hospital - Oklahoma City
North Carolina
- The University of North Carolina at Chapel Hill Center for Heart & Vascular Care - Chapel Hill
- The University of North Carolina Hospitals - Clinical and Translational Research Center Clinic - Chapel Hill
California
- IMD Medical Group - Los Angeles
Connecticut
- Hartford Hospital, JB704 - Hartford
Nevada
- Om Medical - Las Vegas
Ohio
- Metabolic and Atherosclerosis Research Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2013-10-23 |
| Est. Completion | 2016-04-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01968980
The ClinicalTrials.gov registry entry for NCT01968980 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 370 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 171-participant average among 4 other Heterozygous Familial Hypercholesterolemia trials with a reported enrollment target (116% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heterozygous Familial Hypercholesterolemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01968980 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Texas, Oklahoma.
Frequently Asked Questions
What is clinical trial NCT01968980 about?
NCT01968980 is a clinical study titled "A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia". This is a multicenter, randomized study in subjects with heterozygous familial hypercholesterolemia receiving highly effective statins to assess the safety, efficacy and tolerability of Bococizumab (PF-04950615; RN316) to lower LDL-C.
What is the current status of trial NCT01968980?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 370 participants. The study started on 2013-10-23. Estimated completion is 2016-04-15.
What conditions does trial NCT01968980 study?
This clinical trial studies the following conditions: Heterozygous Familial Hypercholesterolemia.
What interventions are being tested in trial NCT01968980?
The interventions under investigation include: Placebo (OTHER), Bococizumab (PF-04950615;RN316) (DRUG).
Who is sponsoring clinical trial NCT01968980?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01968980 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Nevada, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heterozygous Familial Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction
COMPLETED · Phase 3
-
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
COMPLETED · Phase 3
-
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
RECRUITING · Phase 1
-
Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.